US 12083192
Methods for treatment of patients with myelodysplastic syndromes
granted A61KA61K2039/505A61K2121/00
Quick answer
US patent 12083192 (Methods for treatment of patients with myelodysplastic syndromes) held by Actinium Phamaceuticals, Inc. expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Actinium Phamaceuticals, Inc.
- Grant date
- Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K2121/00, A61K31/10, A61K31/198